NCT03144804

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a drug as a possible treatment for p53 mutant metastatic colorectal cancer. The drug involved in this study is: -Lamivudine

Detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved lamivudine for this specific disease but it has been approved for other uses. In this research study, the investigators are studying the effects of lamivudine on this type of cancer. This drug may help prevent the growth and spread of the cancer cells to other parts of the body. The investigators have discovered that this particular type of colon cancer, which has a p53 mutation may be sensitive to treatment with lamivudine by impairing the ability of the cancer cells to grow.

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Lamivudine	This drug may help prevent the growth and spread of the cancer cells to other parts of the body.

Timeline

• Start date: 2017-10-31
• Primary completion: 2020-03-26
• Completion: 2022-09-27
• First posted: 2017-05-09
• Last updated: 2024-06-06
• Results posted: 2021-08-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study